Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

Arg1+ macrophages may play a role in causing alopecia areata.

In this study, the authors used AI-driven methods to identify and prioritize promising therapeutic targets that may address both aging and Glioblastoma Multiforme, proposing CNGA3, GLUD1, and SIRT1 as novel candidates.

This case report presents a patient with idiopathic isolated ACTH deficiency and testicular germ cell tumor, with alopecia areata as an initial symptom, suggesting a potential link between these conditions.

This study found that GPT-4o demonstrated high concordance with in-person and image-based provider assessments in generating SALT scores for alopecia areata, suggesting its potential as an adjunct tool in clinical practice for automating these assessments.

This review discusses recent advancements made in using mouse models to investigate the genetic complexity and pathogenesis of alopecia areata, emphasizing potential new treatment targets, but it reports no new findings.

This study found that Regenera ActivaAMT significantly improved hair growth and patient satisfaction in both men and women with Androgenetic Alopecia, suggesting it may be an effective alternative to hair transplants.

This literature review highlights challenges in managing alopecia areata in the Middle East and Africa, noting significant regional gaps in data, treatment guidelines, and public awareness that impede patient care and emphasize the need for improved support and resources.

This review discusses emerging evidence on azathioprine's efficacy and safety for severe alopecia areata, reporting sustained response in many patients but emphasizing the need for controlled trials.

This case report describes a nine-year-old girl with juvenile dermatomyositis and alopecia areata, suggesting a possible etiological link between these coexisting immune-mediated diseases, a previously unreported association.

This article discusses the potential benefits of GcMAF and oral MAF, developed by "Saisei Mirai", for cancer and other conditions, but reports no new clinical results.

Apremilast may help treat hair loss in alopecia areata.

This study introduces a novel computational model using fuzzy logic and multi-criteria decision-making techniques to create a triage system for androgenetic alopecia management, stratifying patients into seven severity levels and aiding in resource allocation and treatment planning.

In this study, researchers found that inducing mitophagy can alleviate NLRP3 inflammasome activation in outer root sheath cells under conditions of mitochondrial stress, suggesting that targeting mitophagy and inflammasome interactions may offer new therapeutic approaches for alopecia areata.

This review discusses the relevance of human androgen receptor action in sports doping and examines the potential of cell-based biological assays for detecting androgenic anabolic steroid use, without presenting new research findings.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

This article provides new treatment guidelines for AA based on expert consensus while integrating regional healthcare variations, but it reports no new clinical results.

This study found that autologous micrografts using AMT® technology effectively improved symptoms and mobility in patients with early-stage knee osteoarthritis, demonstrating safety and potential benefits at 1- and 6-months post-procedure.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.

This study developed a questionnaire based on Andersen’s behavioral model to explore psychological well-being and mental health help-seeking behaviors among alopecia areata patients from underserved communities, aiming to better understand factors influencing their mental healthcare utilization.

This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

This review compiles existing research on ischemia-modified albumin (IMA) as a biomarker for myocardial ischemia, highlighting current gaps in understanding its formation and detection, with no new clinical results reported.

This consensus provides a framework for standardized diagnosis and treatment of alopecia areata in the Asia Pacific region, recommending specific therapies based on age and disease severity.

This review discusses the epidemiology, pathophysiology, diagnosis, and management of male androgenetic alopecia, noting that combination treatments, including FDA-approved and emerging therapies, may improve outcomes without added side effects.

In this study on tolerant rats, maternal and developmental toxicity from levo-alpha-acetyhnethadol hydrochloride were observed at all doses, without specific fetal toxicity or teratogenic effects.

This study found a significant positive association between higher air quality index values and the incidence of alopecia areata, with a clear dose-response relationship observed among the participants.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.